公开(公告)号：US07273608B2

公开(公告)日：2007-09-25

申请号：US11077978

申请日：2005-03-11

Applicant: Paul J. Yazaki ,  Mark A. Sherman ,  John E. Shively ,  Andrew A. Raubitschek ,  Anna M. Wu

Inventor： Paul J. Yazaki ,  Mark A. Sherman ,  John E. Shively ,  Andrew A. Raubitschek ,  Anna M. Wu

IPC: A61K39/00

CPC classification number: C07K16/3007 ,  A61K2039/505 ,  C07K16/32 ,  C07K16/465 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/626 ,  C07K2317/92 ,  C12N15/1089 ,  G01N33/574

Abstract: Embodiments of the present invention utilize a more efficient CDR grafting technique to generate humanized versions of the T84.66 antibody. The technique used to generate these antibodies utilizes crystallographic structural data to select an immunoglobulin framework having maximum structural overlap with a non-human donor molecule. This technique was used to develop humanized T84.66 antibodies exhibiting in vitro binding affinity and specificity for carcinoembryonic antigen (CEA) nearly identical to that of T84.66 and the ability to specifically target tumors expressing CEA in vivo.

Abstract translation: 本发明的实施方案利用更有效的CDR移植技术来产生人源化版本的T84.66抗体。 用于产生这些抗体的技术利用晶体结构数据来选择与非人供体分子具有最大结构重叠的免疫球蛋白框架。 该技术用于开发显示与T84.66几乎完全相同的癌胚抗原（CEA）的体外结合亲和性和特异性的人源化T84.66抗体，并且具体靶向体内表达CEA的肿瘤的能力。

公开(公告)号：US07776330B2

公开(公告)日：2010-08-17

申请号：US11861093

申请日：2007-09-25

Applicant: Paul J. Yazaki ,  Mark A. Sherman ,  John E. Shively ,  Andrew A. Raubitschek ,  Anna M. Wu

Inventor： Paul J. Yazaki ,  Mark A. Sherman ,  John E. Shively ,  Andrew A. Raubitschek ,  Anna M. Wu

IPC: A61K39/395 ,  C12P21/04 ,  C12P21/08 ,  C07K16/00

CPC classification number: C07K16/3007 ,  A61K2039/505 ,  C07K16/32 ,  C07K16/465 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/626 ,  C07K2317/92 ,  C12N15/1089 ,  G01N33/574

Abstract: Embodiments of the present invention utilize a more efficient CDR grafting technique to generate humanized versions of the T84.66 antibody. The technique used to generate these antibodies utilizes crystallographic structural data to select an immunoglobulin framework having maximum structural overlap with a non-human donor molecule. This technique was used to develop humanized T84.66 antibodies exhibiting in vitro binding affinity and specificity for carcinoembryonic antigen (CEA) nearly identical to that of T84.66 and the ability to specifically target tumors expressing CEA in vivo.

Abstract translation: 本发明的实施方案利用更有效的CDR移植技术来产生人源化版本的T84.66抗体。 用于产生这些抗体的技术利用晶体结构数据来选择与非人供体分子具有最大结构重叠的免疫球蛋白框架。 该技术用于开发显示与T84.66几乎完全相同的癌胚抗原（CEA）的体外结合亲和性和特异性的人源化T84.66抗体，并且具体靶向体内表达CEA的肿瘤的能力。